With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.
Another new year, another half-billion-biobuck transaction between Insilico Medicine and the Italian drugmaker Menarini Group ...
Seasoned advisory group including RNA, translation and commercialisation luminaries.
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and ...
Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at ...
Nimbus Therapeutics Announces Clinical Progress in Oncology Therapeutic Pipeline and Provides Business Updates ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...
The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback